AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04378348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI)
Description: The MI dialogue will begin with an introduction where the LDL is asked about the type of work he does and his concerns regarding dangers in his workplace. This will be followed by a decisional balance exercise where the interviewer will engage the LDL in thinking about the pros and cons of taking jobs with many dangers and jobs with less dangers. Using a figure of a traffic light, the interviewer will proceed to measure how important it is for the LDL to reduce the dangers in his work place and identify his reasons for its importance. Next, the interviewer will measure the LDL's level of confidence in his ability to reduce the dangers in his workplace.Together, they will develop a plan to reduce the dangers in the workplace. Finally, the interviewer will summarize the safety plan to the LDL and will explain that the team will return to the corner in one month to see how the implementation of his plan went and to conduct a post-test survey
Study NCT04378348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Group Activity
Description: Participants will view a figure of a pyramid representing the steps they can take to reduce the dangers in their workplace and the things that are in their control to reduce the dangers followed by pictures of dangerous work environments. They will be engaged in hazard identification and situational awareness by identifying and sharing out loud the dangers they see in the picture. Participants will also engage in problem solving by coming up with strategies they could use to reduce the dangers they identified in the picture and will measure their level of confidence in their ability to implement the strategies they have come up with, should they find themselves in a similar work situation. The group facilitator will summarize what the group has said and what they have learned during the group activity and will ask participants to voluntarily make a personal promise to take concrete steps to reduce the dangers at their work.
Study NCT04378348 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Condition
Description: At control corner sites, we will recruit another 35 Latino day laborer participants.Participants in the control group will receive OSHA pamphlets with standard workplace safety and health information. During our needs assessment survey, we collected information regarding workrelated injuries. Results from this survey indicate the following 4 categories are the highest cause of injury among surveyed Latino day laborers: 1) moving heavy objects, 2) falls, 3) being struck by falling or lying objects, and 4) serious cuts. The OSHA materials that will be distributed to participants will include safety and health information regarding these four topics. Furthermore, given that the LDL are continuously exposed to the sun (e.g., at the corner while waiting for work, at work, and on their way to and from work), heat exposure will also be included in the OSHA materials.
Study NCT01894295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
Study NCT01894295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D analogue
Description: 1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
Study NCT04750746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Conventional Therapy Passive ROM and/or AROM exercises Muscle strengthening; Therapeutics stretching of the shoulder, the elbow, the wrist, and the fingers. Activities of daily living training, including eating, grooming, dressing, toileting, and transfer
Study NCT04750746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Interventional therapy Xbox Kinect (Xbox 360, Microsoft,) For training, programs such as Boxing and Bowling in the Kinect sports pack and Rally Ball, 20,000 Leaks, and Space Pop in the Kinect adventure pack, all of which required the use of the upper extremities, will be selected
Study NCT04184791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Each DBS electrode contact will be reprogrammed in 60hz and High Frequency Stimulation (180hz) in the Levodopa ON (medicated) and OFF (unmedicated) conditions.
Study NCT01913418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suan-Zao-Ren Tang
Description: SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
Study NCT01913418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suan-Zao-Ren Tang placebo
Description: The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
Study NCT02644187 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BF-RhodoLED
Description: Infrared light, with total dose of 37J/cm2.
Study NCT02644187 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aktilite CL128
Description: Infrared light, with total dose of 37J/cm2.
Study NCT02644187 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BF200-ALA/5-aminolevulinic acid
Description: Prodrug applied to whole treatment area previous to illumination with either light source.
Study NCT01639885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2b
Description: 1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
Study NCT01639885 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: p53 SLP
Description: 8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
Study NCT03547089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viveve®
Description: A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
Study NCT01421576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat meal
Description: offer high fat-meal in the morning before drug intake.
Study NCT01421576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fat meal
Description: offer high fat-meal in the morning before drug intake.
Study NCT03494387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 80% versus 30% inspiratory oxygen concentration
Study NCT03494387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: Antioxidants versus placebo
Study NCT04521400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Interferon-beta 1a
Description: Low doseIFN-β1a (Recigen) (Subcutaneous injections of 44μg (12,000 IU) on days 1, 3, 6)
Study NCT02635269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar
Description: 10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
Study NCT04524468 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Conventional 2-D transthoracic echocardiography was performed to all patients
Study NCT01409356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + exercise
Description: Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
Study NCT04392765 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: eXciteOSA
Description: eXciteOSA transoral neurostimulation device
Study NCT02127424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse-driven HIV targeted screening
Study NCT02127424 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current practice
Study NCT01297959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-101 Solution 300 GU/ml
Description: 8 mL of E-101 Solution
Study NCT01297959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution matched to E-101
Study NCT03062969 — intervention group
Intervention type: PROCEDURE
Intervention: Cleavage stage biopsy group
Description: * intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~* Time lapse embryo culture~* Cleavage stage biopsy~* aCGH analysis~* Fresh euploid embryo transfer
Study NCT03062969 — intervention group
Intervention type: PROCEDURE
Intervention: Trophectoderm biopsy group
Description: * ICSI-IVF~* Time lapse embryo culture~* Day 3 zona pellucida opening~* Trophectoderm biopsy~* aCGH analysis~* Frozen-thawed euploid embryo transfer
Study NCT02650869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
Study NCT02650869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breast milk
Description: Normal breast milk will be given as part of standard care
Study NCT01285583 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TRO19622
Description: 2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
Study NCT04414267 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Description: Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
Study NCT04414267 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients susceptible to SARS-CoV-2 infection will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
Study NCT00646477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: titration night
Description: Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events.
Study NCT02535910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
Study NCT02535910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH) D3
Description: Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
Study NCT02535910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects are asked to consume a breakfast without vitamin D
Study NCT03818672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin 550 MG BID
Study NCT02389972 — intervention group
Intervention type: DRUG
Intervention: Dasatinib
Study NCT03932604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial sensing On mode
Description: Single lead VDD-ICD programmed as atrial sensing On mode.
Study NCT01751438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Systemic Therapy (BST)
Description: Group 1 will continue to receive best systemic therapy (BST).
Study NCT01751438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Systemic Therapy (BST) + Surgery or Radiation Therapy
Description: Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
Study NCT01751438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
Study NCT01751438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone Call/Email
Description: Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
Study NCT00265889 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 480 mcg beginning day +5
Study NCT00265889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: 11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
Study NCT00265889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg IV over 2 hours x 2 days
Study NCT00265889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 60 mg/kg, IV
Study NCT00265889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
Study NCT00265889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: autologous-autologous tandem hematopoietic stem cell transplantation
Study NCT00265889 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: radiation therapy
Study NCT03089918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-JNJ-63779586
Description: Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B12
Description: Methylcobalamin Dose: 75 μg/kg every 3 days
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cellulose
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folate
Description: Folinic acid: Dose: 400 µg twice a day (BID)
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B complex
Description: B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: Vitamin C 500 mg
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cod liver oil
Description: Cod liver oil 1/2 teaspoon
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral complex
Description: Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
Study NCT00572741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: carnitine
Description: Acetyl L-Carnitine Dose: 250 mg
Study NCT03195933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cortisol
Description: We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
Study NCT03195933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
Study NCT00696709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: V212
Description: 0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered \~30 days apart
Study NCT00071617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth-Nominated Support Team
Study NCT03288116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scheimplug imaging and contrast and sensitivity test
Description: examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
Study NCT02622854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: plasma exchange
Description: see arm description
Study NCT02622854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: see arm description
Study NCT02122133 — intervention group
Intervention type: DEVICE
Intervention: PC 400
Study NCT05069090 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lockdown and other social distancing measures
Description: During the study period, the Chilean Ministry of Health established a five-step process for social distancing measures. These ranged from full lockdown (step 1) to almost no restrictions (step 5). Even under full lockdown, citizens were able to obtain permits for essential activities. Citizens had a maximum of two permits per week and were obtained in a virtual station of the Chilean Police Force (Carabineros de Chile).
Study NCT02767258 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LACRIBELL®
Description: Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
Study NCT02767258 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIDISIC® GEL
Description: Carbomer based gel, used in the treatment of dry eye.
Study NCT00951275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 6 months
Study NCT00951275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
Description: As prescribed
Study NCT01460940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
Study NCT01460940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
Study NCT00318357 — intervention group
Intervention type: DEVICE
Intervention: Continuation of CRT
Description: Implantation of CRT device and medical treatment according normal hospital routine.
Study NCT00318357 — intervention group
Intervention type: DEVICE
Intervention: Upgrade to CRT
Description: Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
Study NCT03138148 — intervention group
Intervention type: OTHER
Intervention: Routine mechanical ventilation
Description: Routine mechanical ventilation in PICU amid children with acute respiratory failure
Study NCT04510805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NextDose (nextdose.org)
Description: NextDose guided warfarin management taking into consideration covariates (sex, age, weight, height CYP2C9 (rs1057910) and VKORC1 (rs9923231), the dosing and INR history of each patient to predict an individualized dose in accordance with the theory-based warfarin model and target concentration intervention principles.~Initial recommended warfarin dose, up to the first INR, will be the maintenance dose predicted from group values, subsequently the NextDose predicted maintenance dose will be recommended. The treating clinician will also be provided with the NextDose report to inform the choice of the prescribed dose.
Study NCT00778765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Gabapentin Capsules
Study NCT00778765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 mg Gabapentin Capsules
Study NCT01550458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mibefradil
Description: 25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
Study NCT01550458 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
Study NCT01695564 — intervention group
Intervention type: DEVICE
Intervention: LARIAT LAA
Description: The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.